Argatroban description: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Argatroban}} {{CMG}}; {{AE}} {{JH}} ==TITLE== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXO...")
 
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{JH}}
{{CMG}}; {{AE}} {{JH}}


==TITLE==
==Description==


Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5-[(aminoiminomethyl) amino]-1-oxo-2[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2- piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.


The molecular formula of argatroban is C23H36N6O5S•H2O. Its molecular weight is 526.66 g/mol. The structural formula is:
{|
[[File:Argatroban_09|thumb|600px|]]
|}
Argatroban Injection is a sterile, non-pyrogenic, clear, colorless to pale yellow, aqueous solution. It is supplied in a single use, clear glass vial containing 50 mg of argatroban in 50 mL solution. Each mL, contains 1 mg argatroban, 2 mg lactobionic acid, 2 mg L-methionine USP, 8 mg sodium chloride USP, and sodium hydroxide NF (for pH adjustment) in water for injection USP. The pH of the solution is approximately 8.8.


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher =  | date =  | accessdate = }}</ref>
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher =  | date =  | accessdate = }}</ref>

Revision as of 19:51, 4 March 2014

Argatroban
Argatroban® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Description

Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5-[(aminoiminomethyl) amino]-1-oxo-2[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2- piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.

The molecular formula of argatroban is C23H36N6O5S•H2O. Its molecular weight is 526.66 g/mol. The structural formula is:

File:Argatroban 09

Argatroban Injection is a sterile, non-pyrogenic, clear, colorless to pale yellow, aqueous solution. It is supplied in a single use, clear glass vial containing 50 mg of argatroban in 50 mL solution. Each mL, contains 1 mg argatroban, 2 mg lactobionic acid, 2 mg L-methionine USP, 8 mg sodium chloride USP, and sodium hydroxide NF (for pH adjustment) in water for injection USP. The pH of the solution is approximately 8.8.

[1]

Reference

  1. "ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]".

Adapted from the FDA Package Insert.